Abstract: An example method of updating a client dashboarding component of an asset monitoring and reporting system comprises: identifying an update of a client dashboarding component of an asset monitoring and reporting system (AMRS), the client dashboarding component comprising one or more dynamic elements, each dynamic element associated with an asset node; receiving one or more search queries, each search query corresponding to a dynamic element of the one or more dynamic elements; modifying one or more dynamic elements of the client dashboarding component in accordance with the one or more search queries; and updating the client dashboarding component to reflect metric values associated with the modified dynamic elements.

Abstract: An asset monitoring and reporting system (AMRS) implements decoupled update cycle and disparate search frequency dispatch for dynamic elements of an asset monitoring and reporting system. The AMRS identifies occurrence of an update to a visualization of a client dashboarding component of an AMRS, the visualization comprising dynamic elements and corresponding dynamic element searches that are each associated with a search query to be submitted for execution to obtain a value of a metric of an asset node associated with a respective dynamic element. The AMRS further sends a request indicative of the dynamic elements to a server component of the AMRS, receives dynamic element objects for the dynamic elements, the dynamic element objects specifying search queries corresponding to the dynamic elements, modifies dynamic element searches of the dashboarding component in accordance with the search queries, and stores a definition of the visualization as control information.

Abstract: The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.

Abstract: The invention relates to sustained release formulations comprising 11-?4-?2-(2-hydroxyethoxy)ethyl!-1-piperazinyl!dibenzo?b,f! ?1,4!thiazepine or a pharmaceutically acceptable salt thereof, to methods of treating psychotic states and hyperactivity utilizing the sustained release formulations and to a process for preparing the sustained release formulations.